NOSH-aspirin
NOSH-aspirin (NBS-1120) is an orally active hybrid molecule that releases nitric oxide and hydrogen sulfide. NOSH-aspirin inhibits pancreatic cancer cell proliferation and induces apoptosis. NOSH-aspirin inhibits cancer cell growth and suppresses NF-κB and FoxM1 in a mouse model of pancreatic cancer. NOSH-aspirin also alleviates motor deficits and dopaminergic neuron degeneration in a rat model of Parkinson's disease. NOSH-aspirin reduces neuroinflammation caused by microglial and astrocytic activation. NOSH-aspirin can be used in research on cancers such as pancreatic cancer and neurological diseases such as Parkinson's disease.
For research use only. We do not sell to patients.
- CAS No.: 1357362-67-4
- Formula: C20H15NO7S3
- Molecular Weight:477.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
50 nM
Compound: NOSH-1
|
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
Cytotoxicity against human A549 cells after 24 hrs by MTT assay
|
[PMID: 22916316] |
| BXPC-3 | IC50 |
57 nM
Compound: NOSH-1
|
Cytotoxicity against human BxPC3 cells expressing COX1 and COX2 after 24 hrs by MTT assay
Cytotoxicity against human BxPC3 cells expressing COX1 and COX2 after 24 hrs by MTT assay
|
[PMID: 22916316] |
| HCT-15 | IC50 |
50 nM
Compound: NOSH-1
|
Cytotoxicity against COX deficient human HCT15 cells after 24 hrs by MTT assay
Cytotoxicity against COX deficient human HCT15 cells after 24 hrs by MTT assay
|
[PMID: 22916316] |
| HCT-15 | IC50 |
57 nM
Compound: 1
|
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 26323873] |
| HT-29 | IC50 |
48 nM
Compound: 1
|
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 24 hrs by MTT assay
|
[PMID: 26323873] |
| HT-29 | IC50 |
48 nM
Compound: NOSH-1
|
Cytotoxicity against human HT-29 cells expressing COX1 and COX2 after 24 hrs by MTT assay
Cytotoxicity against human HT-29 cells expressing COX1 and COX2 after 24 hrs by MTT assay
|
[PMID: 22916316] |
| Jurkat | IC50 |
100 nM
Compound: NOSH-1
|
Cytotoxicity against human Jurkat cells expressing COX1 and COX2 after 24 hrs by MTT assay
Cytotoxicity against human Jurkat cells expressing COX1 and COX2 after 24 hrs by MTT assay
|
[PMID: 22916316] |
| LNCaP | IC50 |
88 nM
Compound: NOSH-1
|
Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay
Cytotoxicity against human LNCAP cells after 24 hrs by MTT assay
|
[PMID: 22916316] |
| MCF7 | IC50 |
280 nM
Compound: NOSH-1
|
Cytotoxicity against human MCF7 cells expressing ER after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells expressing ER after 24 hrs by MTT assay
|
[PMID: 22916316] |
| MDA-MB-231 | IC50 |
100 nM
Compound: NOSH-1
|
Cytotoxicity against ER deficient human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against ER deficient human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 22916316] |
| MIA PaCa-2 | IC50 |
47 nM
Compound: NOSH-1
|
Cytotoxicity against COX deficient human MIAPaCa2 cells after 24 hrs by MTT assay
Cytotoxicity against COX deficient human MIAPaCa2 cells after 24 hrs by MTT assay
|
[PMID: 22916316] |
| SK-BR-3 | IC50 |
75 nM
Compound: NOSH-1
|
Cytotoxicity against ER deficient human SKBR3 cells after 24 hrs by MTT assay
Cytotoxicity against ER deficient human SKBR3 cells after 24 hrs by MTT assay
|
[PMID: 22916316] |
| SW480 | IC50 |
60 nM
Compound: NOSH-1
|
Cytotoxicity against human SW480 cells expressing COX1 after 24 hrs by MTT assay
Cytotoxicity against human SW480 cells expressing COX1 after 24 hrs by MTT assay
|
[PMID: 22916316] |
Chemical Information
-
CAS No. 1357362-67-4
-
Molecular Weight 477.53
-
Formula C20H15NO7S3
-
SMILES
O=C(OC1=CC=C(C(SS2)=CC2=S)C=C1)C3=CC=CC=C3OC(CCCO[N+]([O-])=O)=O
-
Synonyms
NBS-1120
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Lee M, et al. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders. Glia. 2013 Oct;61(10):1724-34. [Content Brief]
[2]. Chattopadhyay M, et al. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS. Biochem Pharmacol. 2020 Jun;176:113857. [Content Brief]
[3]. Firouzan B, et al. NOSH-aspirin (NBS-1120) attenuates motor defects and dopaminergic neuron degeneration in a rat model of Parkinson's disease. Eur J Pharmacol. 2025 Sep 5;1002:177733. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)